Inventiva (IVA) Competitors $3.70 -0.06 (-1.60%) As of 04/30/2025 01:09 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVA vs. XNCR, AVXL, ABCL, DAWN, CVAC, QURE, PRAX, IMNM, BCAX, and REPLShould you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Xencor (XNCR), Anavex Life Sciences (AVXL), AbCellera Biologics (ABCL), Day One Biopharmaceuticals (DAWN), CureVac (CVAC), uniQure (QURE), Praxis Precision Medicines (PRAX), Immunome (IMNM), Bicara Therapeutics (BCAX), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry. Inventiva vs. Xencor Anavex Life Sciences AbCellera Biologics Day One Biopharmaceuticals CureVac uniQure Praxis Precision Medicines Immunome Bicara Therapeutics Replimune Group Xencor (NASDAQ:XNCR) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership. Which has more risk & volatility, XNCR or IVA? Xencor has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Is XNCR or IVA more profitable? Inventiva has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Inventiva's return on equity of 0.00% beat Xencor's return on equity.Company Net Margins Return on Equity Return on Assets Xencor-232.77% -30.92% -21.74% Inventiva N/A N/A N/A Do insiders & institutionals believe in XNCR or IVA? 19.1% of Inventiva shares are owned by institutional investors. 5.2% of Xencor shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer XNCR or IVA? Xencor received 485 more outperform votes than Inventiva when rated by MarketBeat users. However, 82.76% of users gave Inventiva an outperform vote while only 73.24% of users gave Xencor an outperform vote. CompanyUnderperformOutperformXencorOutperform Votes50973.24% Underperform Votes18626.76% InventivaOutperform Votes2482.76% Underperform Votes517.24% Which has preferable valuation & earnings, XNCR or IVA? Inventiva has lower revenue, but higher earnings than Xencor. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXencor$110.49M7.10-$126.09M-$3.51-3.14Inventiva$9.20M21.11-$119.51MN/AN/A Does the media refer more to XNCR or IVA? In the previous week, Xencor had 5 more articles in the media than Inventiva. MarketBeat recorded 10 mentions for Xencor and 5 mentions for Inventiva. Xencor's average media sentiment score of 1.15 beat Inventiva's score of 0.66 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer XNCR or IVA? Xencor currently has a consensus price target of $32.86, indicating a potential upside of 198.16%. Inventiva has a consensus price target of $10.40, indicating a potential upside of 181.08%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe Xencor is more favorable than Inventiva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xencor 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryXencor beats Inventiva on 9 of the 17 factors compared between the two stocks. Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVA vs. The Competition Export to ExcelMetricInventivaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$194.17M$6.89B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E RatioN/A7.4422.4418.48Price / Sales21.11242.66394.66103.91Price / CashN/A65.8538.1834.62Price / Book-5.526.516.774.25Net Income-$119.51M$143.21M$3.22B$248.23M7 Day Performance-3.65%3.97%3.09%3.29%1 Month Performance26.24%0.37%-0.14%2.43%1 Year Performance17.09%2.59%17.98%5.54% Inventiva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVAInventiva1.9363 of 5 stars$3.70-1.6%$10.40+181.1%+17.1%$194.17M$9.20M0.00100Gap DownXNCRXencor3.24 of 5 stars$10.60+9.3%$33.86+219.4%-47.4%$746.90M$110.49M-3.31280Upcoming EarningsAnalyst ForecastPositive NewsAVXLAnavex Life Sciences3.8167 of 5 stars$8.76-2.1%$44.00+402.3%+160.3%$745.16MN/A-15.9340Upcoming EarningsPositive NewsGap DownABCLAbCellera Biologics2.5888 of 5 stars$2.45+1.2%$7.50+206.1%-31.0%$730.07M$28.83M-4.02500Upcoming EarningsGap DownDAWNDay One Biopharmaceuticals2.4717 of 5 stars$7.14+4.4%$32.29+352.2%-54.5%$723.67M$131.16M-6.9360Upcoming EarningsCVACCureVac4.1276 of 5 stars$3.21+2.9%$10.00+211.5%+40.9%$720.13M$535.18M5.84880Analyst ForecastPositive NewsQUREuniQure2.4031 of 5 stars$13.29+2.2%$38.80+191.9%+234.7%$718.68M$27.12M-2.68500Upcoming EarningsShort Interest ↑Gap DownHigh Trading VolumePRAXPraxis Precision Medicines3.4744 of 5 stars$35.34+4.6%$123.33+249.0%-31.4%$712.56M$8.55M-3.43110Positive NewsIMNMImmunome2.5927 of 5 stars$8.00+1.1%$25.14+214.3%-37.5%$695.61M$9.04M-0.9940Positive NewsGap DownBCAXBicara TherapeuticsN/A$12.65+4.0%$32.43+156.4%N/A$689.72MN/A0.0032Analyst RevisionNews CoveragePositive NewsGap DownREPLReplimune Group4.1827 of 5 stars$8.77+9.8%$19.43+121.5%+54.0%$675.42MN/A-2.86210Positive News Related Companies and Tools Related Companies XNCR Competitors AVXL Competitors ABCL Competitors DAWN Competitors CVAC Competitors QURE Competitors PRAX Competitors IMNM Competitors BCAX Competitors REPL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.